Publicacións nas que colabora con Luis Alfonso Gurpide Ayarra (16)

2024

  1. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2021

  1. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2019

  1. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  2. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

  2. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism

    OncoImmunology, Vol. 5, Núm. 1

2013

  1. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein

    Cancer Research, Vol. 73, Núm. 1, pp. 139-149

2011

  1. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

2010

  1. Selection of extreme phenotypes: The role of clinical observation in translational research

    Clinical and Translational Oncology, Vol. 12, Núm. 3, pp. 174-180

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array

    British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883

  3. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

2007

  1. Nuevos tratamientos para el carcinoma renal

    Anales del sistema sanitario de Navarra, Vol. 30, Núm. 3, pp. 393-403